Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease
- 29 March 2006
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 97 (3) , 737-746
Abstract
Recently, alterations in dopamine signaling have been implicated in Huntington's disease. In this work, dopamine release and uptake was measured in striatal slices from the R6/2 transgenic mouse model of Huntington's disease using fast‐scan cyclic voltammetry at carbon‐fiber microelectrodes. Dopamine release in brain slices from 6‐week‐old R6/2 mice is substantially reduced (53% of wild type), while dopamine uptake is unaffected. In agreement with this, R6/2 mice injected with the dopamine uptake inhibitor cocaine exhibited a blunted motor activity response (54% of wild type). At 10 weeks of age, an even more dramatic motor activity decrease in response to cocaine injection (21% of wild type) was observed. Moreover, the pre‐drug activity of 10‐week‐old R6/2 mice was significantly reduced (by 37%) compared with 6‐week‐old R6/2 mice. Striatal dopamine release decreased with age, indicating that progressive alterations in dopaminergic pathways may affect motor activity. The inhibition constants of cocaine and methamphetamine (METH) determined in brain slices differed little between genotype or age group, suggesting that the decreased responses to cocaine and METH arise from compromised dopamine release rather than differences in uptake or drug action. Collectively, these data demonstrate (i) a reduction in the ability of dopamine terminals to release dopamine and (ii) the importance of this attenuation of release on the motor symptoms of Huntington's disease.Keywords
This publication has 54 references indexed in Scilit:
- The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient β-cell mass and exocytosisHuman Molecular Genetics, 2005
- Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic miceBrain Research, 2004
- Striatal neurochemical changes in transgenic models of Huntington's diseaseJournal of Neuroscience Research, 2002
- Dopamine and cognitive functioning: Brain imaging findings in Huntington’s disease and normal agingScandinavian Journal of Psychology, 2001
- Subsecond Adsorption and Desorption of Dopamine at Carbon-Fiber MicroelectrodesAnalytical Chemistry, 2000
- Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease miceProceedings of the National Academy of Sciences, 2000
- Decreased striatal monoaminergic terminals in Huntington diseaseNeurology, 2000
- Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's diseaseAnnals of Neurology, 1997
- The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's diseaseNature Genetics, 1993
- DOPAMINE AND NORADRENALINE IN POST‐MORTEM BRAIN IN HUNTINGTON'S DISEASE AND SCHIZOPHRENIC ILLNESSActa Psychiatrica Scandinavica, 1980